

Announcing New Editorial Leadership in Clinical Proteomics and Biomarker Discovery

We are delighted to announce the appointment of Dr. Michael A. Gillette from the Broad Institute of M.I.T. and Harvard as a new Associate Editor in the expanding area of clinical proteomics and biomarker discovery.

Dr. Gillette will assume a leadership position in proteomics focused on advancing our knowledge and understanding of human biology and disease. He will bring new strength to our Associate Editors (AEs) that is complementary to all other existing AEs and provide us a global overview of developments foreseen in this important field, as well as insights on current community needs and expanded opportunities from his knowledge of medicine and bioanalytical technologies.

Dr. Gillette's credentials are impressive. He is a Senior Group Leader in Proteomics and Biomarker Discovery at the Broad Institute of MIT and Harvard, a Pulmonary and Critical Care Medicine Attending and Associate Physician at the Massachusetts General Hospital, and Assistant Professor of Medicine at Harvard Medical School.

As noted, he has a particular interest in clinical proteomics and biomarker development. With other Broad colleagues, Dr. Gillette has been involved in the development and implementation of all aspects of a coherent biomarker discovery and verification pipeline. Dr. Gillette and Dr. Steven A. Carr together have led Broad Institute efforts in breast and ovarian cancer proteomic biomarker discovery, and in molecular characterization of infectious diseases of high international health import, including pediatric febrile illness and tuberculosis. He was an active member of the Broad CPTAC2 team that performed proteogenomic characterization of TCGA breast cancer specimens, and is a co-principal investigator on the Broad CPTAC3 effort focused on proteogenomic characterization of non-small cell lung cancer. Dr. Gillette holds an



FIG. 1. **Michael A. Gillette, MCP Associate Editor.**

M.D. and Ph.D. (Neurophysiology) from Harvard University, Cambridge, MA; M.Sc. (Human Biology) and M.A. (Psychology and Philosophy) degrees from Oxford University, Oxford, UK; and a B.A. (Biology and Philosophy) from Carleton College, Northfield, MN.

Finally, he brings a blend of clinical knowledge and current practice, experimental design, mass spectrometry and diverse laboratory skills, and over a decade of direct experience to his leadership roles in proteomic tumor analysis and biomarker development.

Please join us in welcoming Dr. Gillette to our team.

Al Burlingame, Steve Carr, and Anne-Claude Gingras.